Tadeo-Escobar I, Ángeles-Morales V, Soto-Hernandez JL, Cárdenas HGA

Idioma: Español
Referencias bibliográficas: 32
Paginas: 6-13
Archivo PDF: 402.20 Kb.

RESUMEN

Antecedentes: Clostridioides difficile es un patógeno reemergente que causa diarrea nosocomial a nivel mundial, particularmente en países industrializados.
Objetivo: Presentar una serie de casos clínicos de infección por Clostridioides difficile en un centro de referencia neurológico.
Método: estudio retrospectivo y observacional de casos de infección por C. difficile (ICD) en el Instituto Nacional de Neurología de enero de 2016 a diciembre de 2018.
Resultados: se incluyeron 16 pacientes con CDI durante el periodo de estudio. Todos ellos tuvieron el antecedente de terapia antimicrobiana de amplio espectro en las 6 semanas previas al inicio de los síntomas. Más de la mitad de la población afectada correspondió a mujeres. El principal diagnóstico de admisión fue enfermedad cerebrovascular, seguido de enfermedades infecciosas. Otros factores de riesgo (adicionales al uso de antimicrobianos) fueron inhibidores de bomba de protones, corticosteroides y obesidad.
Conclusiones: los pacientes con afección neurológica son proclives al desarrollo de diarrea nosocomial debido a un conjunto de factores de riesgo, incluyendo uso concomitante de corticosteroides, inhibidores de bomba de protones, obesidad/diabetes (previos al uso de antibióticos de amplio espectro). Se requieren programas de gerencia de antibióticos para asegurar un uso racional de éstos y con ello disminuir el riesgo de diarrea nosocomial en esta población.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Heinlen L, Ballard JD. Clostridium difficile infection. Am J Med Sci. 2010; 340(3):247-52

2. Wiegand PN, Nathwani D, Wilcox MH, et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systemic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;8(1):1-14

3. Ma GK, Brensinger CM, Wu Q, et al. Increasing incidence of multiply recurrent Clostridium difficile infection in the United States: A cohort study. Ann Intern Med 2017;167(3):152-158

4. Reigadas Ramirez E, Bouza ES. Economic burden of Clostridium difficile infection in European countries. Adv Exp Med Biol 2018;1050:1-12

5. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014;69(4):881-891

6. Abou Chakra CN, Pepin J, Sirard S, et al. Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review. PLoS One 2014;9:e98400. doi.10.1371/journal.pone.0098400

7. McDonald EG, Milligan J, Frenette C, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent Clostridium difficile infection. JAMA Intern Med 2015; 175:784-791

8. Bloomfield MG, Sherwin JC, Gkrania-Klotsas E. Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review. J Hosp Infect 2012;82:1-12

9. Petrosillo N. Tackling the recurrence of Clostridium difficile infection. Med Mal Infect 2018;48(1):18-22

10. Camacho-Ortiz A, Ponce de Leon A, Sifuentes-Osornio J. Enfermedad asociada a Clostridium difficile en America Latina. Gac Med Mex 2009;145(3):223-229

11. Ramirez-Rosales A, Cantú-Llanos E. Mortalidad intrahospitalaria en pacientes con diarrea asociada a infección por Clostridium difficile. Rev Gastroenterol Mex 2012;77:60-65

12. Dávila LP, Garza-Gonzalez E, Rodríguez-Zulueta P, et al. Increasing rates of Clostridium difficile infection in Mexican hospitals. Braz J Infect Dis 2017;21(5):530-534

13. Morfin-Otero R, Garza-Gonzalez E, García García G, et al. Clostridium difficile infection in patients with chronic kidney disease in Mexico. Clin Nephrol 2018;90:350-356

14. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections. Am J Gastroenterol 2013;108(4):478-498

15. Clements AC, Magalhães RJ, Tatem AJ, et al. Clostridium difficile PCR rybotype 027: assessing the risk of further worldwide spread. Lancet Infect Dis 2010;10:395-404

16. Hung YP, Lee JC, Lin HJ, et al. Clinical impact of Clostridium difficile colonization. J Microbiol Immunol Infect. 2015;48(3):241-248

17. Wijarnpreecha K, Sornprom S, Thongprayoon C, et al. Nasogastric tube and outcomes of Clostridium difficile infection: A systemic review and meta-analysis. J Evid Based Med. 2018:11:40-45

18. Wijarnpreecha K, Sornprom S, Thongprayoon C, et al. The risk of Clostridium difficile associated diarrhea in nasogastric tube insertion: A systematic review and meta-analysis. Dig Liver Dis. 2016;48(5):468-472.

19. Banaei N, Anikst V, Schroeder LF. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015; 372(24):2368-2369

20. Ho J, Dai RZW, Kwong TNY, et al. Disease burden of Clostridium difficile infections in adults Hong Kong, China, 2006-2014. Emerg Infect Dis. 2017;23:1671-1679

21. Lopardo G, Morfin-Otero R, Moran-Vazquez II, et al. Epidemiology of Clostridium difficile: a hospital-based descriptive study in Argentina and Mexico. Braz J Infect Dis. 2015;19(1):8-14

22. Dasenbrock HH, Bartolozzi AR, Gormley WB, et al. Clostridium difficile infection after subarachnoid hemorrhage: A Nationwide-Analysis. Neurosurgery. 2016;78:412-420

23. Tripathy S, Nair Rothburn M. Clostridium difficile associated disease in a neurointensive care unit. Front Neurol. 2013;4:82

24. Cornely OA, Nathwani D, Ivanescu C, et al. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69:2892-2900

25. Hefazi M, Patnaik MM, Hogan WJ, et al. Safety and efficacy of fecal microbiota transplant for recurrent Clostridium difficile infection in patients with cancer treated with cytotoxic chemotherapy: A single-Institution retrospective case series. Mayo Clin Proc 2017;92(11):1617-1624

26. Fischer M, Kao D, Kelly C, et al. Fecal microbiota transplantation is safe and efficacious for recurrent or refractory Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 2016;22:2402-2409

27. Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term follow up study on fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: A multicenter experience. J Clin Gastroenterol 2016;50(5):398-402

28. Konturek PC, Koziel J, Dieterich W, et al. Successful therapy of Clostridium difficile infection with fecal microbiota transplantation. J Physiol Pharmacol. 2016;67(6):859-866

29. Kelly CR, Jhunnah C, Fischer M, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065-1071

30. Fisher M, Kao D, Mehta SR, et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: A multicenter study. Am J Gastroenterol 2016;111:1024-1031

31. Meighani A, Hart BR, Mittal C, et al. Predictors of fecal transplant failure. Eur J Gastroenterol Hepatol 2016;28:826-830

32. Dehlhom-Lambertsen E, Hall BK, Jørgensen SMD, et al. Cost saving following faecal microbiota transplantation for recurrent Clostridium difficile infection. Therap Adv Gastroenterol 2019:12:1756284819843002. doi: 10.1177/1756284819843002